19 reports of this reaction
1.7% of all MOMETASONE FUROATE MONOHYDRATE reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for MOMETASONE FUROATE MONOHYDRATE, manufactured by CVS WOONSOCKET PRESCRIPTION CENTER, INCORPORATED. There are 19 FDA adverse event reports linking MOMETASONE FUROATE MONOHYDRATE to DYSPNOEA. This represents approximately 1.7% of all 1,126 adverse event reports for this drug.
Patients taking MOMETASONE FUROATE MONOHYDRATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for MOMETASONE FUROATE MONOHYDRATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for MOMETASONE FUROATE MONOHYDRATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 19 FDA reports for MOMETASONE FUROATE MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.7% of all adverse event reports for MOMETASONE FUROATE MONOHYDRATE, making it a notable side effect.
If you experience dyspnoea while taking MOMETASONE FUROATE MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.